Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intellia Therapeutics, Inc. (NASDAQ: NTLA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Current Reports on Form 8-K that detail material events in its clinical and corporate development. As a clinical-stage gene editing company, Intellia uses SEC filings to report key information about its CRISPR-based programs, financial results and significant regulatory interactions.
Recent 8-K filings furnished by Intellia describe positive Phase 1 and Phase 1/2 data for its investigational in vivo CRISPR therapies, nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). These filings summarize trial designs, patient numbers, biomarker reductions, clinical outcome measures and safety observations over multi-year follow-up. Other 8-Ks discuss the initiation and status of global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO, as well as the FDA’s clinical hold on the MAGNITUDE programs for nex-z.
Intellia also uses Form 8-K to furnish quarterly financial results, including collaboration revenue, research and development expenses, general and administrative expenses and cash, cash equivalents and marketable securities. Additional filings report equity inducement grants made under the company’s 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4), and changes involving senior executives.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and can be paired with AI-powered summaries that highlight the most important points in dense regulatory documents. Users can quickly understand the implications of Intellia’s 8-K disclosures, track the evolution of its nex-z and lonvo-z programs, and monitor material events that may affect NTLA’s risk profile and development timeline.
Intellia Therapeutics entered an underwriting agreement for a public offering of 16,744,187 shares of common stock at $10.75 per share, with underwriters exercising a 30‑day option for an additional 2,511,628 shares. The company estimates net proceeds of about $194.6 million.
Intellia plans to use the funds to advance clinical development and prepare for commercial launch of its lead programs, support other pipeline research, pursue potential acquisitions, and for working capital and general corporate purposes. It expects these proceeds, together with existing cash and collaboration funding, to fund operations at least into 2028.
Intellia also reported preliminary unaudited cash, cash equivalents and marketable securities of about $517.2 million as of March 31, 2026, including roughly $33.6 million in net proceeds from at‑the‑market stock sales during the quarter.
Intellia Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 10, 2026 may vote on three main items: electing three class I directors, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board unanimously recommends voting in favor of all three proposals. The proxy statement also explains virtual attendance and voting procedures, quorum and vote standards, board composition, governance practices, and committee structures, including audit, compensation, nominating and science and technology committees.
Intellia Therapeutics Inc Schedule 13G filed by Vanguard Capital Management reports beneficial ownership of 5,945,571 shares of common stock, representing 5.03% of the class. The filing shows sole voting power for 861,466 shares and sole dispositive power for 5,945,571 shares. The filing lists CUSIP 45826J105 and is signed April 30, 2026.
Intellia Therapeutics is offering 16,744,187 shares of common stock. The prospectus supplement dated April 28, 2026 sets a public offering price of $10.75 per share and shows estimated net proceeds to the company of approximately $169.2 million before expenses.
The underwriters have a 30-day option to purchase up to an additional 2,511,628 shares. The registration assumes 116,317,060 shares outstanding as of December 31, 2025. The offering proceeds are intended to advance clinical development, prepare for commercial launch, fund R&D and general corporate purposes.
Intellia Therapeutics Inc Schedule 13G shows Vanguard Portfolio Management beneficially owned 6,266,007 shares of common stock, representing 5.3% of the class as of 03/31/2026. The filing states Vanguard entities exercise dispositive power over these shares and that the position includes securities held for Vanguard funds and managed accounts. The filing was signed on 04/29/2026.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics is offering $150,000,000 of its common stock under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement is part of an automatic shelf registration (Form S-3ASR, File No. 333-275740) and states the shares will trade on Nasdaq under the symbol NTLA.
The supplement cites key program updates for lonvo-z (NTLA-2002), including positive Phase 3 topline results and a rolling BLA submission, and provides preliminary cash figures: approximately $517.2 million in cash, cash equivalents and marketable securities as of March 31, 2026. Shares outstanding were 116,317,060 as of December 31, 2025.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.
Intellia Therapeutics reported positive Phase 3 HAELO trial results for its in vivo CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. In the 80‑patient, placebo‑controlled study, lonvo-z achieved an 87% reduction in HAE attack rate versus placebo between weeks 5 and 28 and 62% of treated patients were completely attack‑free and off prophylactic therapy in that period. All 52 patients in the lonvo-z arm saw attack‑rate reductions, and early crossover data showed attack rates approaching zero in both arms. Safety appeared favorable, with no serious adverse events or grade ≥3 treatment‑emergent events reported in the lonvo-z group and mainly mild or moderate infusion‑related reactions. Intellia has initiated a rolling biologics license application with the FDA and is preparing to complete the submission in the second half of 2026 and for a potential U.S. launch in the first half of 2027, if approved.
Intellia Therapeutics, Inc. amended its bylaws, effective April 7, 2026. The changes let shareholders fix facially obvious errors in timely notices of director nominations or other proposals, and require the company to alert them when such deficiencies exist so they can be cured.
The updated bylaws also make federal district courts in the United States the exclusive forum for complaints asserting causes of action under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless Intellia agrees in writing to a different forum.
Intellia Therapeutics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares and 0% beneficial ownership of Common Stock following an internal realignment. The filing states that, effective with the realignment and in reliance on SEC Release No. 34-39538, certain Vanguard subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own those subsidiary-held securities. The filing is dated 03/13/2026 with a signature on 03/27/2026.